AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 102 min read$LLY

Hakim Anat sold $6.0M of LLY (indirect holdings)

Hakim Anat (EVP, GC & Secretary) sold 5,000 indirectly-held shares of ELI LILLY & Co (LLY) at $1190.00 ($5.95M total) on 2026-08-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hakim Anat
Published Aug 10, 2026, 8:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 8:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LLY
Neutral
medium confidence
Mentioned
$LLY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LLYNeutralLow
01

Why it matters

The newest disclosed fact is the specific 10b5-1 sale size, price, and post-transaction holdings for Hakim Anat.

02

Market read

This provides incremental transparency on insider activity but does not introduce new operational or financial guidance.

03

What to watch

Because the sale is indirect and pre-arranged, traders should avoid over-weighting it versus upcoming LLY-specific catalysts (earnings, guidance, trial/regulatory updates).

Relevance 5/10Novelty 4/10Timing: filed 2026-08-10 after-hours; transaction dated 2026-08-07

Background

The article is an SEC Form 4 insider transaction disclosure for Eli Lilly & Co, reported via EDGAR.

Company-level read

Ticker impact

$LLYNeutralMedium confidence
Context

Hakim Anat, LLY EVP, GC and Secretary, sold 5,000 shares at $1,190/share under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any effect is likely limited to short-term sentiment around the filing.

Evidence & confidence

The filing is a Form 4 insider transaction with an explicit pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary sales.

Market effects

Sector

No direct sector read-through; this is company-specific insider transaction data.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Insider sales can still reflect personal liquidity needs rather than bearish views, especially when tied to a 10b5-1 schedule.

Key entities

  • issuer
    LLY

    Eli Lilly & Co, the company whose insider transaction is disclosed.

  • insider
    Hakim Anat

    EVP, GC and Secretary at LLY, reported an open-market sale under a pre-arranged 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LLY insider trading history →

Related articles

SEP 24
$LLYLowAI 8/10

FDA approval for Lilly’s weekly insulin Onswik, shares dip

The FDA approved Eli Lilly's (LLY) once-weekly insulin Onswik for type 2 diabetes. The drug, already approved in the EU, Mexico, and Japan, aims to reduce injections from 365 to 52 per year. Despite the approval, LLY shares dipped 1.6%. Lilly's revenue and net income have surged, reaching $22.97bn and $7.1bn respectively in Q2 2026. The company faces competition from Novo Nordisk's Awiqli in the weekly insulin market.

financial-news.co.uk2 min
SEP 24
$LLYHighAI 9/10

New once-weekly insulin injection for type 2 diabetes wins FDA approval

Eli Lilly's once-weekly insulin, Onswik, received FDA approval for type 2 diabetes. It reduces annual injections by over 300 compared to daily insulin. Trials with 3,400+ adults showed A1C declines similar to daily insulin glargine. Onswik will be available in the US in pre-filled pens. According to Lilly, it offers an alternative to daily injections.

thenews.com.pk2 min